Anti-Fungal Treatment Study Updated by NexMed (NEXM)
NexMed, Inc. (Nasdaq: NEXM) today announced that it has completed its post hoc analysis of NM100060, the Company's topically-applied treatment for onychomycosis (nail fungus). NexMed seeks to pursue signing a partner for further development of the product.
NM100060 has previously been tested in approximately 2,000 patients enrolled in three Phase 3 clinical studies conducted by Novartis. On July 7, 2009, the Company announced the mutual decision with Novartis to terminate the exclusive, global licensing agreement for NM100060.
NM100060 has previously been tested in approximately 2,000 patients enrolled in three Phase 3 clinical studies conducted by Novartis. On July 7, 2009, the Company announced the mutual decision with Novartis to terminate the exclusive, global licensing agreement for NM100060.
You May Also Be Interested In
- DISH Network (DISH) Sued by Networks for 'Commercial Skipping' Feature
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
